Shattuck Labs

Edit info

Founded: 2016

Location: Durham, NC

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Ovarian cancer

Drug types: ONC, IMM

Lead product: SL-172154

Funding: $232M IPO Oct 2020; $118M Jun 2020; $46M May 2018

Investors: Redmile Group

shattucklabs.com

linkedin.com

job board

Drug notes:

Also second combo Clin1 ovarian cancer, Clin1 AML, MDS; undisclosed programs Clin0 oncology, autoimmune conditions

About:

Shattuck Labs is developing treatments for cancer and autoimmune diseases by pioneering novel bi-functional fusion proteins. The tumor necrosis factor receptor (TNFr) with its involvement in immune regulation has been a popular therapeutic target. Using their Agonist Redirected Checkpoint (ARC) technology, Shattuck is creating molecules that both unlock the TNFr superfamily in a unique fashion while simultaneously blocking an immune checkpoint. As both targets on the molecule can be substituted, Shattuck is efficiently creating thousands of therapeutics which in turn can address multiple areas of high unmet clinical need. Currently, Shattuck’s portfolio includes over 400 bi-functional fusion proteins.